文献速递青光眼

全身用药变化及其对眼压的影响——古腾堡健康研究结果

Change in Systemic Medication and its Influence on Intraocular Pressure - Results From the Gutenberg Health Study.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

古腾堡健康研究是一项在德国开展的人群为基础的前瞻性观察性队列研究,纳入9633名参与者的19161只眼,分析基线(2007-2012)与5年随访(2012-2017)期间全身用药变化与眼压变化的关系。结果显示新开始使用选择性β受体阻滞剂者眼压变化更低(-0.31 mm Hg,P<0.001),停用者眼压升高(+0.28 mm Hg,P=0.02),且选择性β受体阻滞剂剂量变化与眼压变化存在剂量-反应关系(-0.16 mm Hg/100 mg,P=0.02)。他汀类和钙通道阻滞剂与眼压变化的关联可归因于合并用药。

要点

  • 新开始使用选择性β受体阻滞剂与5年眼压变化降低相关(-0.31 mm Hg,P<0.001)。
  • 停用选择性β受体阻滞剂与眼压升高相关(+0.28 mm Hg,P=0.02)。
  • 选择性β受体阻滞剂剂量变化与眼压变化存在剂量-反应关系(-0.16 mm Hg/100 mg,P=0.02)。

核心结论

  • 全身使用选择性β受体阻滞剂与人群水平的眼压变化相关,而其他全身用药与眼压变化的关联可由合并用药或血压变化解释。
  • 作者认为,进行眼压监测和管理的患者应常规询问全身用药的变化。

研究设计与样本

  • 古腾堡健康研究是一项在德国开展的人群为基础的前瞻性观察性队列研究。
  • 分析纳入9633名参与者的19161只眼,在基线检查(2007-2012)和5年随访检查(2012-2017)时用非接触式眼压计测量眼压并记录全身用药。
  • 采用多变量回归分析分析关联,并计算选择性β受体阻滞剂剂量变化与5年眼压变化的剂量-反应关系。

主要发现

  • 新开始使用选择性β受体阻滞剂的参与者眼压变化更低(-0.31 mm Hg,P<0.001)。
  • 停用选择性β受体阻滞剂的参与者眼压升高(+0.28 mm Hg,P=0.02)。
  • 他汀类和钙通道阻滞剂与眼压变化的关联可归因于合并用药。
  • 选择性β受体阻滞剂摄入变化与眼压变化存在剂量-反应关系(-0.16 mm Hg/100 mg,P=0.02)。

临床怎么用

  • 作者认为,进行眼压监测和管理的患者应常规询问全身用药的变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to investigate the relationship between the change in systemic medication and intraocular pressure (IOP) on a population-based level. METHODS: The Gutenberg Health Study is a population-based prospective observational cohort study in Germany. As part of the baseline examination (2007-2012) and 5-year follow-up examination (2012-2017), IOP was measured by non-contact tonometry. Systemic medication was recorded at both time points. Multivariable regression analyses were carried out to analyze associations. Moreover, we calculated the dose-response relationship for the dosage change of selective beta-blockers with IOP change over 5 years. RESULTS: The analysis population included 19,161 eyes of 9633 participants. IOP change was lower in participants with new intake of selective beta-blockers (-0.31 mm Hg, P < 0.001) and increased in those with discontinuation of selective beta-blocker intake (+0.28 mm Hg, P = 0.02). Associations between IOP change and statins and calcium channel blockers (CCBs) could be attributed to co-medications. There was a dose-response relationship for change in selective beta-blocker intake and change in IOP (-0.16 mm Hg/100 mg, P = 0.02). CONCLUSIONS: Use of systemic selective beta-blockers is associated with an IOP change on a population level, whereas the association with other systemic medications on IOP change could be explained by co-medication use or change in blood pressure. Patients undergoing IOP monitoring and management should routinely be asked about changes in systemic medications.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Laspas P, Hartmann A, Scholz I, et al. Change in Systemic Medication and its Influence on Intraocular Pressure - Results From the Gutenberg Health Study. Invest Ophthalmol Vis Sci. 2024. PMID: 39625443. doi:10.1167/iovs.65.14.4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。